07Nov

Cytox appoints new CCO

cytox-logo

Oxford and Manchester, UK – Cytox, a precision medicine company focused on developing solutions to identify individuals most at risk for developing Alzheimer's disease and dementia, today announced the appointment of Antony Hill as Chief Commercial Officer.

“We are pleased to welcome Tony Hill to the Cytox team,’ commented Cytox CEO, Dr Richard Pither, He joins us at a very exciting time for Cytox. This year we announced several important new collaborations and funding from Innovate UK and presented results on our recent advancements at all the major conferences, including how we identify Alzheimer’s disease risk in ApoE3 homozygote individuals, and also identify those individuals most likely to progress from mild cognitive impairment to Alzheimer’s.

“Tony has been involved in the diagnostics and molecular life sciences industry for 30 years, with senior roles in sales and marketing in international diagnostics and molecular life science companies including TwistDx Ltd (part of Abbott Diagnostics), Diasorin Molecular, Innogenetics and Sigma-Aldrich. He will greatly strengthen our management team and enable us to progress our partnerships and develop our clinical products.”

Related

Reduce Your Costs for Biological Sample Transport

How do you package your send-away pathology samples? Are you spending too much time and money on pac...

Read More >

Genedrive Receives NHS Grant

The UK NHS National Institute for Health Research in June 2018 have offered Professor Bill Newman an...

Read More >

EKF introduces mobile data management solution for the DiaSpect Tm POC hemoglobin analyzer

Cardiff, UK – 13th November 2017 – EKF Diagnostics, the global in vitro diagnostics company, today...

Read More >

IPP signs a significant deal with BBI Solutions on Ginolis LFDA assembly line delivery

Industrial Production Processes (IPP) Ltd today announced that it has signed a contract with BBI Sol...

Read More >

OGT unveils reliable somatic CNV detection for CLL with new NGS panel

SureSeq™ CLL + CNV - comprehensive CLL genomic profiling from a single assay

Read More >